Pneumocystis carinii as a cause of pneumonia in the immunocompromised host, has become increasingly important since the onset of the AIDS epidemic. Characterization of specific antigens to which the host immune response is mounted, may result in the development of new therapeutic modalities. A prominent class of antigens of rat-derived P. carinii migrate between 45 and 55 kDa. Recently I have cloned a gene that encodes an antigen of the 45 - 55 kDa class of rat-derived P. carinii. Infected animals mount a vigorous humoral and cell mediated response to this 55 kDa antigen but nothing is known of its location or cellular function. I hypothesize that the 55 kDa antigen : i) is functionally important to P. carinii and ii) may play an important role in the pathogenesis of infection and the host immune response to the organism. This project will attempt to define the cellular function of the 55 kDa antigen and to characterize the host response to this antigen.
The specific aims of the project will be: (1) To study the expression of the 55 kDa antigen in rat- derived P. carinii and examine its role in promoting adherence to lung cells; (2) To examine interaction of the 55 kDa antigen with other P. carinii and host proteins by molecular approaches; (3) To characterize the humoral and cellular immune response to the 55 kDa antigen; and (4) To clone the homologous gene from human-derived P. carinii. I will identify the cellular localization of the 55 kDa antigen and characterize its expression by Indirect Fluorescent Antibody (IFA) techniques, Immuno- Electron Microscopy (IEM). If shown to be a surface moiety, a cellular approach will test specific peptide sequences of the 55 kDa antigen, such as an Arg-Gly-Asp (RGD) sequence located at position 80, for adherence to eukaryotic cells. To examine the functional interaction with other P. carinii and host proteins, molecular approaches utilizing (i) the two hybrid system in yeast, (ii) the random peptide expression library will be used. The humoral and cellular immune responses to the 55 kDa antigen will be characterized. B- and T-cell determinants will be identified and responses to these epitopes examined after natural infection and following immunization. Work on this recombinant antigen of P. carinii will identify the role of this antigen in the biology of P. carinii and in the pathogenesis of P. carinii infection. An understanding of the function of this antigen and its role in the immune response might provide information enabling modulation of the growth and metabolism of the organism or alteration of the immune response.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AI034759-02
Application #
2069919
Study Section
AIDS and Related Research Study Section 2 (ARRB)
Project Start
1994-04-01
Project End
1999-03-31
Budget Start
1995-04-01
Budget End
1996-03-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Cincinnati
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Fox, D; Smulian, A G (2001) Plasminogen-binding activity of enolase in the opportunistic pathogen Pneumocystis carinii. Med Mycol 39:495-507
Fox, D; Smulian, A G (2000) Mkp1 of Pneumocystis carinii associates with the yeast transcription factor Rlm1 via a mechanism independent of the activation state. Cell Signal 12:381-90
Smulian, A G; Sullivan, D W; Theus, S A (2000) Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization. Microbes Infect 2:127-36
Fox, D; Smulian, A G (1999) Mitogen-activated protein kinase Mkp1 of Pneumocystis carinii complements the slt2Delta defect in the cell integrity pathway of Saccharomyces cerevisiae. Mol Microbiol 34:451-62
Broomall, K R; Morris, R E; Walzer, P D et al. (1998) Zymolyase treatment exposes p55 antigen of Pneumocystis carinii. J Eukaryot Microbiol 45:284-9
Theus, S A; Smulian, A G; Steele, P et al. (1998) Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine 16:1149-57
Theus, S A; Sawhney, N; Smulian, A G et al. (1998) Proliferative and cytokine responses of human T lymphocytes isolated from human immunodeficiency virus-infected patients to the major surface glycoprotein of Pneumocystis carinii. J Infect Dis 177:238-41
Smulian, A G; Keely, S P; Sunkin, S M et al. (1997) Genetic and antigenic variation in Pneumocystis carinii organisms: tools for examining the epidemiology and pathogenesis of infection. J Lab Clin Med 130:461-8